The record
J&J recommended the FDA adopt its x-ray-diffraction-based J4-1 method while knowing of a more sensitive pre-concentration method, and internal documents state the company withheld the concentration technique because it would not be in worldwide company interests.
Claim scope
A verbatim internal statement of intent to secure adoption of a less sensitive method before more sensitive techniques matured. The court separately quotes the admission that “concentrating techniques w[ould] permit a good laboratory to identify asbestos or tremolite in a talc sample”, and that the pre-concentration method was rejected because it made it “possible to arrive at levels of detectability of asbestos in talc in the [parts per million] range” and would likely “be too sensitive.” The court also states that in the early 1970s the defendants DID use the pre-concentration method on their own products and detected tremolite.
What this source does not establish
The opinion does not date these internal documents individually beyond “in the 1970s” / “the early 1970s”. It does not establish that the FDA adopted J4-1 because of this lobbying — the FDA never finalised a talc rule (see the Federal Register findings).
Limitations
Ingham recites each internal document under the express predicate "According to Plaintiffs' evidence" and under the standard "Viewing the evidence in the light most favorable to the verdict." The court's HOLDING is that Plaintiffs made a submissible case for punitive damages; it is NOT an independent judicial finding that each recounted document says what plaintiffs said it says. Phrase as: 'the Missouri Court of Appeals, upholding the punitive award, recounted plaintiffs' evidence that...' NOTE: Ingham spells the method inconsistently, using both “J-41” and “J4-1” in the same passage. The correct designation, confirmed by the CTFA's own October 1976 document as quoted in McNeal and by PMID 31095409, is J4-1.
Source
Case Citation — Ingham v. Johnson & Johnson, No. ED107476 (Mo. Ct. App. E.D. June 23, 2020)